Skip to main content
. Author manuscript; available in PMC: 2020 Sep 11.
Published in final edited form as: Leukemia. 2020 Feb 24;34(9):2342–2353. doi: 10.1038/s41375-020-0764-6

Figure 4. Genetic abnormalities in AML samples associate with differential sensitivity ex vivo to Ibrutinib + Venetoclax.

Figure 4.

Comparisons of IBR+VEN sensitivities (% of max AUC) with respect to categorical variables (panel A) and continuous variables (panel B). Categorical variables were compared by Mann-Whitney test; circles indicate difference of median AUC and bars indicate 95% confidence interval. Continuous variables were correlated by Spearman rank test. C. Scatter plots of IBR+VEN AUC with expression levels of their respective canonical drug target: BTK and BCL2.